Glaukos Corporation

NYSE:GKOS

Medical - Devices

Healthcare
$233.08 -0.14%

-$0.18 today

Market cap
$13.80B
Beta
0.81
P/E (TTM)
-39.0
EPS (TTM)
-$3.26
52W Low $73.16High $148.11

Volume 1.12M

Average 0.94M

GKOS Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Glaukos CorporationNYSE: GKOS

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $28.87M rose 60.2% year over year, ahead of the +36.6% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 50.8% from the prior quarter. Over 3 fiscal years it compounded at +17.9% a year.

Context

  • Stock-based compensation amounted to 12.5% of revenue in FY2025, down 0.6 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +60.2% holds above the trailing-twelve-month pace of +36.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$28.87M+50.8% QoQ
Last fiscal yearDec 2025
$63.22M+25.9% YoY
LTMJun 2026
$80.22M+36.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+60.2%——
1 year+25.9%——
3-year CAGR+17.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
63.22M USD
Year-over-year change
+25.9%
4-year CAGR
+20.3%

Stock-Based Compensation vs competitors

How GKOS compares with its peers on the latest reported figures

  • GKOS's LTM Jun 2026 stock-based compensation of $80.22M is the largest of the 9 companies compared; the peer median is $30.54M.
  • Its year-over-year change of +36.6% is the highest of 8, against a peer median of -0.5%.
  • Stock-based compensation amounts to 13.1% of revenue for GKOS, versus a peer median of 14.7%.
GKOS Competitors Peer median
Stock-Based Compensation for GKOS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GKOSGlaukos CorporationLTM Jun 2026$80.22M +36.6%+17.9%13.1%
BLCOBausch + Lomb CorporationLTM Jun 2026$72M -33.9%+33.9%1.4%
OCULOcular Therapeutix, Inc.LTM Mar 2026$48.31M +35.8%+36.5%92.8%
ALCAlcon Inc.LTM Sep 2026$42M -154.5%+5.0%0.4%
RXSTRxSight, Inc.LTM Mar 2026$32.42M +19.7%+40.5%25.4%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M -0.5%+25.3%416.2%
STAASTAAR Surgical CompanyLTM Apr 2026$29.4M +9.3%+14.5%10.1%
SGHTSight Sciences, Inc.LTM Mar 2026$11.67M -30.6%+0.2%14.7%
SGPSpyGlass Pharma, Inc. Common StockFY2025$2.79M ———
Peer median (excluding GKOS) $30.54M-0.5%+25.3%14.7%

Competitors are the stored peer set for GKOS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.59M)(99.2M)(134.66M)(146.37M)(133.66M)
Depreciation & Amortization34.42M35.95M37.98M39.92M42.35M
Deferred Income Tax(1.03M)(54K)(120K)(216K)(6.49M)
Stock-Based Compensation30.15M38.56M43.53M50.21M63.22M
Change in Working Capital3.58M(13.45M)(10.13M)(39.47M)(31.55M)
Accounts Receivables1.7M(3.14M)(3.84M)(21.97M)(53.02M)
Inventory(7.7M)(15.47M)(4.83M)(18.79M)2.65M
Accounts Payables12.45M7.21M1.31M21K18.82M
Other Working Capital(2.87M)(2.05M)(2.77M)1.26M0
Other Non-Cash Items7.19M5.11M5.65M34.62M19.79M
Operating Cash Flow24.71M(33.08M)(57.76M)(61.32M)(46.34M)
Capital Expenditures(47.79M)(30.27M)(20.25M)(6.3M)(7.67M)
Acquisitions (Net)3K151K038K(12.44M)
Purchases of Investments(215.29M)(59.26M)(265.59M)(189.96M)(232.29M)
Sales of Investments206.92M135.16M303.1M247.2M196.94M
Other Investing Activities(2.08M)(1.01M)(3.17M)(3.15M)(22.16M)
Investing Cash Flow(58.23M)44.78M14.1M47.83M(77.61M)
Debt Repayment(659K)(527K)(711K)51.34M(1.12M)
Common Stock Issued30.94M9.21M19.03M46.76M21.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities8.98M(2.43M)(3.27M)(6.56M)(8.13M)
Financing Cash Flow39.26M6.25M15.04M91.54M11.89M
Effect of Forex Changes(1.62M)870K2.56M(1.89M)804K
Net Change in Cash4.11M18.82M(26.06M)76.16M(111.26M)
Free Cash Flow(23.08M)(63.35M)(78.01M)(67.62M)(54.01M)

Glaukos Corporation

NYSE:GKOS

Intrinsic Alpha fair value

Locked

Current Price

$233.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.